DocWire News Editors

DocwireNews

A study of risk distribution scores for patients with chronic myeloid leukemia (CML) indicated that risk distribution according to EUTOS long-term survival (ELTS) and Sokal score and concordance between the scores was different between different age groups of patients with the disease.The ELTS is the most recent prognostic score for risk stratification of patients with CML and has been shown to be superior for predicting overall survival (OS) and leukemia-related survival. However, data are limited and differences between the two systems are small.Fausto Castagnetti, MD, PhD, of the University of Bologna, Italy, recently presented findings of a study comparing the two systems at the 60th ASH Annual Meeting and Exposition.Many prognostic scores have been proposed for risk stratification; the ELTS score is based on a large cohort of patients treated with imatinib as a first-line therapy, and is specifically developed to discriminate the probability of dying from CML.&ldquo;Given the different weight of the variable &lsquo;age&rsquo; in ELTS and Sokal score formulations, we hypothesized a different predictive value of the two scores in young patients (under 30 years old), adults (between the ages of 30 and 64), and elderly patients (those 65 years and older),&rdquo; Castagnetti said.Of the 904 included patients, 559 had been treated with imatinib as first-line therapy and 345 had been treated with nilotinib as first-line therapy. Patients were enrolled in six multicenter studies (NCT00481052, NCT00769327, NCT01535391, NCT00514488, NCT00510926, observational trial CML/023) conducted by the GIMEMA CML WP.The majority of patients (70%) were adults, with 22% (n=202) elderly; median follow-up was 6.4 years.In the young and adult patient groups, the risk distribution was comparable between the Sokal and ELTS, but differed greatly in elderly patients in predicting low and intermediate risk patients. In elderly patients (&ge; 65 years old), the Sokal score suggested 9%, 70%, and 21% were at low, intermediate, or high risk, respectively. This differed considerably from the ELTS score, where 24%, 54%, and 22% were at low, intermediate, or high risk, respectively. Only 8% of low ELTS patients had a low Sokal score, and only 48% of high ELTS score had a high Sokal score.&ldquo;Half of the intermediate and high Sokal risk patients were potentially misclassified,&rdquo; Castagnetti said. &ldquo;One-third of patients stratified by ELTS score have a different Sokal score (in any risk category). These discrepancies were more evident in elderly patients.&rdquo;Similar outcomes were found when stratifying patients by molecular response by risk. Overall, both scores were able to predict significantly different probabilities of MR3, MR4, OS, and leukemia-related survival, but in elderly patients only the ELTS score was able to predict the achievement of MR3 (99%, 87%, and 75% in low-, intermediate-, and high-risk patients, respectively; P=.001) and MR4 (82%, 61%, and 50% in low-, intermediate-, and high-ELTS score patients, respectively; P=.005).Interestingly, in elderly patients both scores predicted the OS, while only the ELTS score predicted a significantly different leukemia-related death probability (cumulative incidence 2%, 6%, and 14% in low-, intermediate-, and high-risk patients, respectively; P=.049).&ldquo;Consequently, especially in elderly patients, the use of ELTS score is strongly recommended to assess the baseline disease-risk and to select patient candidates to a frontline treatment with second-generation TKIs, minimizing the risk of unnecessary over-treatment,&rdquo; Castagnetti said.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients

ASH Annual Meeting 2018

A study of risk distribution scores for patients with chronic myeloid leukemia (CML) indicated that risk distribution according to EUTOS long-term survival (ELTS) and Sokal ...

The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe